Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Mark Foletta
AddedMar 31, 2024
UpdatedMay 31, 2026
Mark Foletta

Mark Foletta

Board Member, Enanta Pharmaceuticals

CrunchbaseLinkedIn

Mark Foletta's Career

Enanta Pharmaceuticals
Enanta Pharmaceuticals

Watertown, MA, US

Board Member· Board
AMN Healthcare
AMN Healthcare

Dallas, TX, US

Board Member· Board
Dexcom
Dexcom

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Mark Foletta's Career

Enanta Pharmaceuticals
Enanta Pharmaceuticals
Public$84.6M1601995Watertown, MA, US
Board Member· Board

Leadership at Enanta Pharmaceuticals

Terry VanceTerry VanceBoard Member
Jay R. LulyJay R. LulyCEO
Kristine PetersonKristine PetersonBoard Member
Gregory L. VerdineGregory L. VerdineFounder
Bruce CarterBruce CarterBoard Member

Similar to Enanta Pharmaceuticals

Anthera PharmaceuticalsAnthera PharmaceuticalsHayward, CA, USPharmaceuticalsest. 2004Anthera PharmaceuticalsHayward, CA, US · est. 2004

Anthera Pharmaceuticals: A US biopharma firm specializing in inflammation and autoimmune disease treatments.

Public · $101.5M21
Entrada TherapeuticsEntrada TherapeuticsBoston, MA, USBiologics, Therapeuticsest. 2016Entrada TherapeuticsBoston, MA, US · est. 2016

Entrada Therapeutics: A global biotech firm developing intracellular biologics for devastating diseases.

Public · $201.6M130
Intercept PharmaceuticalsIntercept PharmaceuticalsNew York City, NY, USPharmaceuticalsest. 2002Intercept PharmaceuticalsNew York City, NY, US · est. 2002

Intercept Pharmaceuticals: An American biopharma firm specializing in synthetic bile acid analogs for chronic liver diseases.

Public · $970M341
Theravance BiopharmaTheravance BiopharmaSouth San Francisco, CA, USDrug Developmentest. 1996Theravance BiopharmaSouth San Francisco, CA, US · est. 1996

Theravance Biopharma develops and commercializes small molecule medicines for various therapeutic areas.

Public · $663.2M111
AMN Healthcare
AMN Healthcare
Public3k1985Dallas, TX, US
Board Member· Board

Leadership at AMN Healthcare

Steve FrancisSteve FrancisFounder
Cary GraceCary GraceCEO
Paul WeaverPaul WeaverBoard Member
Cary GraceCary GraceBoard Member
Doug WheatDoug WheatBoard Member
Jeff HarrisJeff HarrisBoard Member

Similar to AMN Healthcare

LocumTenensLocumTenensAlpharetta, GA, USRecruiting, Staffingest. 1995LocumTenensAlpharetta, GA, US · est. 1995

LocumTenens.com: A staffing firm specializing in filling gaps in healthcare facilities.

375
Dexcom
Dexcom
Public$1.4B7.6k1999San Diego, CA, US
Board Member· Board

Leadership at Dexcom

Bridgette HellerBridgette HellerBoard Member
Kyle MaladyKyle MaladyBoard Member
Karen DahutKaren DahutBoard Member
Eric TopolEric TopolBoard Member
John BurdJohn BurdFounder
Steve AltmanSteve AltmanBoard Member

Similar to Dexcom

GlumetricsGlumetricsIrvine, CA, USGlucose Monitors, Medical Devicesest. 2005GlumetricsIrvine, CA, US · est. 2005

GluMetrics Inc.: A US-based medical device company specializing in innovative glucose monitoring solutions.

Series A · $68.2M30
GlysensGlysensSan Diego, CA, USGlucose Monitorsest. 1998GlysensSan Diego, CA, US · est. 1998

San Diego-based GlySens, Inc. manufactures implantable glucose monitors for enhanced diabetes care across the US.

Series D · $34M75
Tandem Diabetes CareTandem Diabetes CareSan Diego, CA, USMedical Devicesest. 2006Tandem Diabetes CareSan Diego, CA, US · est. 2006

Tandem Diabetes Care: A U.S. healthcare firm specializing in insulin infusion therapy devices.

Public2.6k
Ascensia Diabetes CareAscensia Diabetes CareBasel, Basel-Stadt, CHDiabetes Care, Health Solutionsest. 2016Ascensia Diabetes CareBasel, Basel-Stadt, CH · est. 2016

Ascensia Diabetes Care: A global firm from Basel, dedicated to empowering diabetes patients with innovative health solutions.

1.5k

Mark Foletta's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Mark Foletta

Michael YangMichael YangCEO · ViaCyteAndre MarionAndre MarionBoard Member · SingulexKenneth GiacinKenneth GiacinBoard Member · StemcyteFred MermelsteinFred MermelsteinBoard Member · SanaRx BiotherapeuticsPeter LeonardiPeter LeonardiCo-Founder · OmniCyteJonas WangJonas WangBoard Member · Stemcyte